About This Calculator

The Carboplatin Dose Calculator utilizes the Calvert formula to determine the total dose of carboplatin (in mg) required to achieve a specific systemic exposure, defined by the area under the concentration-time curve (AUC). This method is the standard of care for carboplatin dosing, as it accounts for variations in a patient’s renal function, which is the primary route of elimination for the drug.

This tool is designed for healthcare professionals to support clinical decision-making. All calculations should be independently verified before use in a clinical setting.

Outputs Explained

The primary output of the calculator is the Total Carboplatin Dose, expressed in milligrams (mg). This value is derived from the Calvert formula:

Total Dose (mg) = Target AUC × (GFR + 25)

• Target AUC (mg/mL·min): Your desired level of drug exposure.
• GFR (mL/min): The patient’s Glomerular Filtration Rate, a measure of kidney function.
• The “+ 25” term: Represents the non-renal clearance of carboplatin.

How to Use the Calculator

To use the tool effectively, follow these steps:

1. Select the Target AUC: Choose a standard AUC value from the dropdown or select “Custom” to enter a specific value based on the treatment protocol and patient characteristics.
2. Determine GFR Method:
   • Enter Measured GFR: If you have a direct GFR measurement (e.g., from a 24-hour urine collection or nuclear medicine scan), select this option and enter the value.
   • Calculate eGFR: If a measured GFR is not available, select this option to estimate the GFR using the Cockcroft-Gault formula. You will need to input the patient’s age, sex, weight, and serum creatinine.
3. Review GFR Capping: Decide whether to apply the common institutional practice of capping the GFR at 125 mL/min. This is a safety measure to prevent potential overdosing in patients with exceptionally high renal function.
4. Calculate: The tool will automatically compute the total carboplatin dose based on your inputs.

Dosing Overview

Carboplatin dosing is unique among chemotherapy agents because it targets a specific systemic exposure (AUC) rather than being based on body surface area (BSA). The Calvert formula, developed in 1989, established this relationship between AUC, GFR, and the total dose. Thrombocytopenia is the primary dose-limiting toxicity of carboplatin and is closely correlated with the AUC. Therefore, accurate GFR assessment is critical for safe and effective dosing.

Switching or Treatment Changes

Adjustments to carboplatin dosing, including changes in target AUC or switching between chemotherapy regimens, must be made according to established clinical protocols and under the guidance of an experienced oncologist. Dosing may be modified in subsequent cycles based on observed toxicities (particularly hematologic) and treatment response.

Missed Dose Information

Management of a delayed or missed carboplatin infusion requires clinical judgment. The decision to proceed with a delayed dose, adjust the schedule, or omit the dose depends on the treatment protocol, the length of the delay, and the patient’s clinical status. Consult institutional guidelines or the treating oncologist for specific instructions.

Safety Alerts

Frequently Asked Questions

What is a typical target AUC for carboplatin?

The target AUC varies by cancer type and treatment regimen. It typically ranges from 4 to 7 mg/mL·min. For example, in combination with paclitaxel for ovarian cancer, an AUC of 5 or 6 is common. Lower AUCs may be used in heavily pre-treated patients or in combination with other myelosuppressive agents.

Why is the GFR sometimes capped at 125 mL/min?

Capping the GFR at 125 mL/min is a common safety practice. The original Calvert formula was not validated in patients with GFRs significantly above this level. In patients with very high renal function (supra-normal GFR), the uncapped formula could potentially calculate an excessive dose, increasing the risk of severe toxicity. The cap provides a conservative upper limit for dosing.

Which weight should be used in the Cockcroft-Gault formula?

The choice of weight (actual, ideal, or adjusted) can be controversial. Most institutions recommend using the actual body weight unless the patient is obese (e.g., >125% of ideal body weight), in which case an adjusted body weight is often preferred. Always follow institutional guidelines.

Can this calculator be used for pediatric patients?

No. The Calvert and Cockcroft-Gault formulas were developed and validated in adult populations. Pediatric carboplatin dosing requires specialized formulas (e.g., the Schwartz formula for GFR estimation) and should only be managed by pediatric oncology specialists.

What if the serum creatinine is very low?

In patients with low muscle mass (e.g., elderly, cachectic), a very low serum creatinine level may not accurately reflect renal function, leading to an overestimation of GFR by the Cockcroft-Gault formula. In such cases, some guidelines recommend rounding up the serum creatinine to a minimum value (e.g., 0.7 or 0.8 mg/dL) to avoid calculating an excessively high dose.

Is the Cockcroft-Gault formula the only way to estimate GFR?

While the Calvert formula was originally developed using GFR from chromium-51 EDTA clearance, the Cockcroft-Gault formula is widely used in clinical practice as an acceptable estimate. Other eGFR equations like the MDRD or CKD-EPI are generally not recommended for drug dosing as they are normalized to body surface area and may be less accurate in this context.

References

1. Calvert AH, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7(11):1748-56. doi: 10.1200/JCO.1989.7.11.1748
2. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41. doi: 10.1159/000180580
3. U.S. Food and Drug Administration. Carboplatin Injection Prescribing Information. Access data on Drugs@FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020452s008lbl.pdf
4. National Cancer Institute. Carboplatin – NCI Drug Dictionary. https://www.cancer.gov/about-cancer/treatment/drugs/carboplatin